This invention comprises a pharmaceutical dosage form of, and method of improving dissolution in a substantially aqueous environment/medium of, a low melting highly lipophilic drug/s or its/their pharmaceutically acceptable salts, comprising a solid dispersion further comprising of at least one low melting highly lipophilic drug, at least one surfactant, at least one water soluble dispersant and at least one oxide/s of third row element of periodic table or other pharmaceutically acceptable inert solid powder that is non-cohesive in nature and has an ability to adsorb lipophilic ingredients on its surfaces. The pharmaceutical dosage form of this invention comprises dissolution rate more than 80% in 15 minutes of the low melting highly lipophilic drug Orlistat from its adsorbates in a dissolution test in 900ml of 0.5% of Sodium Chloride containing 3.0% Sodium Lauryl Sulphate, pH 6.0 containing 1- 2 drops of n-octanol/10 litres, in a USP 2 Type apparatus (Paddle) with coil wire sinker at a speed of 75 RPM and temperature of 37.0°C± 0.5°C.
